



भारतीय
प्रौद्योगिकी
संस्थान
काशी हिन्दू विश्वविद्यालय



INDIAN
INSTITUTE OF
TECHNOLOGY
BANARAS HINDU UNIVERSITY

Prof. Pradip Paik, B.Tech. (C.U), M.Tech. & Ph.D. (IIT-K)
Full Professor
Coordinator of IPR Cell
Associate DEAN (Research and Development)
Prof. of School of Bio-Medical Engineering

Varanasi, U.P., 221 005, India

Phone.: 08500109932(m)

Fax: +91-.-

Email: paik.bme@iitbhu.ac.in, pradip.paik@gmail.com

Ref:

Paik/IIT(BHU)/Ph.D./03

Date: 14th May, 2025

This is to certify that **Ms. Sukanya Patra**, Research Scholar (Roll no. **18021501**), performed Ph.D. dissertation under my supervision at the School of Biomedical Engineering, Indian Institute of Technology (IIT), Banaras Hindu University (BHU). The dissertation entitled: "**Development of Amino acid based Copolymeric Nanoparticles for Organ Targeting Delivery of Drugs and Tissue Regeneration**" is a **bonafide record of research work carried out by her under my supervision and guidance**. This dissertation work has not been submitted previously in part or full to any other Institute or University for the award of any Degree or Diploma. Further, it can be declared that this dissertation is free from plagiarism (report attached).

It is also certified that the student has fulfilled all the requirements to submit this dissertation.

Further, parts of this dissertation work have been filed for patents or published in peer reviewed journals to fulfil the requirement of degree and all rights reserve to the IIT(BHU), Varanasi, India.

Dr. Pradip Paik
Professor
School of Biomedical Engineering,
Indian Institute of Technology, (BHU)
Varanasi

आचार्य/PROFESSOR
जैव चिकित्सा अभियांत्रिकी स्कूल
SCHOOL OF BIOMEDICAL ENGG.
भारतीय प्रौद्योगिकी संस्थान (का.हि.वि.)
INDIAN INSTITUTE OF TECHNOLOGY (B.H.U.)
वाराणसी-221005/VARANASI-221005

Declaration by the Candidate

I, **Ms. Sukanya Patra**, Ph.D. Scholar (Roll no. **18021501**), certify that the work embodied in this Dissertation: "**Development of amino acid based co-polymeric Nanoparticles for Organ Targeting Delivery of Drugs and Tissue Regeneration**", is my own bonafide work that carried out by me under the supervision of **Prof. PRADIP PAIK**, School of Biomedical Engineering, Indian Institute of Technology (BHU), Varanasi, India, at the School of Biomedical Engineering, Indian Institute of Technology (BHU), Varanasi, India.

I further declare that I have faithfully acknowledged the research works and have been cited them whichever have been followed to carry out the work of this Dissertation.

This dissertation is free from plagiarism and has not been submitted previously in part or in full to this or any other University or Institution for the award of any degree or diploma.

Place: IIT (BHU), Varanasi

Date: 14/05/2025

Sukanya Patra
(Ms. Sukanya Patra)

CERTIFICATE BY the SUPERVISOR

It is certified that the above statement made by **Ms. Sukanya Patra**, Ph.D. Scholar (Roll no. **18021501**) is true to the best our knowledge.

Pradip Paik
(Supervisor)
Dr. Pradip Paik
Professor
School of Biomedical Engineering,
Indian Institute of Technology (BHU), Varanasi, India

14/05/2025
आचार्य/PROFESSOR
जैव चिकित्सा अभियांत्रिकी स्कूल
SCHOOL OF BIOMEDICAL ENGG
भारतीय प्रौद्योगिकी संस्थान (का.हि.वि.)
INDIAN INSTITUTE OF TECHNOLOGY (B.H.U.)
वाराणसी-221005/VARANASI-221005

S.K. Kumar
14/05/25
(COORDINATOR)

School of Biomedical Engineering,
Indian Institute of Technology (BHU), Varanasi, India
समन्वयक/CO-ORDINATOR
जैव चिकित्सा अभियांत्रिकी स्कूल
SCHOOL OF BIOMEDICAL ENGG
भारतीय प्रौद्योगिकी संस्थान (का.हि.वि.)
INDIAN INSTITUTE OF TECHNOLOGY (B.H.U.)
वाराणसी-221005/VARANASI-221005

COPYRIGHT TRANSFER CERTIFICATE

Title of the Thesis: **Development of amino acid based co-polymeric Nanoparticles
for Organ Targeting Delivery of Drugs and Tissue
Regeneration**

Name of the Student: **Ms. Sukanya Patra**

Copyright Transfer

The undersigned hereby assigns to the Indian Institute of Technology (BHU), Varanasi, all rights under copyright that may exist in and for the above thesis submitted for the award of the Doctor of Philosophy.

Date: ^{14th}..... May, 2025

Place: IIT (BHU), Varanasi

Sukanya Patra
Signature of the Student

(Ms. Sukanya Patra)

Note: However, the author may reproduce or authorize others to reproduce material extracted verbatim from the thesis or derivative of the thesis for author's personal use provided that the source and the Institute's copyright notice are indicated.

ACKNOWLEDGEMENTS

I would like to take this opportunity to sincerely express my gratitude to everyone who has supported and guided me throughout my research journey. I am deeply thankful to the many individuals whose invaluable assistance and encouragement have played a significant role in shaping my thesis into its current form.

I would like to express my heartfelt gratitude to my Ph.D. supervisor, Prof. Pradip Paik, for his unwavering support, guidance, and encouragement throughout my research journey. Your expertise and insightful feedback have been invaluable in shaping my work and helping me navigate challenges. I am particularly grateful for the time you have dedicated to mentoring me and fostering my academic growth. Your passion for research and commitment to excellence have inspired me to strive for greater heights. Thank you for believing in me and for being an exceptional mentor. This achievement would not have been possible without your assistance.

I would like to express my appreciation to my research progress evaluation committee (RPEC) members, Dr. Sanjeev K. Mahto and Dr. Ashutosh Dubey, for their insightful remarks, advice and kind cooperation during this work. I would like to extend my sincere thanks to faculty members of the School of Biomedical Engineering, IIT(BHU) Prof. Prasun K. Roy, Prof. Neeraj Sharma, Dr. Shiru Sharma, Dr. Sanjay Kumar Rai, Dr. Marshal, Dr. Sudip Mukherjee, Dr. Jac Fredo, Dr. Deepesh Kumar, Dr. Brijesh Kumar, Dr. Gowri Balachander and Dr. Bhriugu Kumar Lahkar. I would like to sincerely thank to all the supporting staff of the School for their kind help whenever I required.

I would like to extend my sincere thanks to Prof. Pralay Maiti, Dr. Ruchi Chawla, Dr. Alakh Nirajan Sahu, Dr. Debdip Bhandary and Dr. Malkhey Verma from IIT (BHU) and BHU for their valuable ideas and guidance during my Ph.D. work.

I would like to thank Prof. Rajiv Prakash and Dr. Kamallesh Kumar Singh, In-Charge, Central Instrument Facility Centre and his team members for providing all the characterization facilities on time with precision, without which this work was not possible.

I would like to thank to my seniors, Dr. Monika Singh, Dr. Munendar Sing Tomar, Dr. Somdutta, Dr. Prem Shankar Gupta, and Dr. Kirti Wasnik for their support in the lab during the experiments. I want to sincerely thank my amazing lab mate, Divya Pareek, for her constant support and cheerful attitude throughout the ups and downs of my Ph.D. journey. Her encouragement has been a great source of strength during both the good and challenging times. I truly value her friendship and the important role she has played in making this difficult process more enjoyable and fulfilling.

I would also like to thank all my juniors Gurmeet, DD, Aman, Taniya, Anjali, Sundar, Shivani, Jyotirmayee, and Aniket for their extended support, stimulating discussions and maintaining a cheerful environment in the lab.

I am eternally grateful to my parents and brother for their love, encouragement, and belief in me throughout this journey. Their sacrifices, both big and small, created the foundation upon which I could pursue my goals. Thank you for your constant support, understanding, and always being my biggest cheerleader. This achievement is as much yours as it is mine. I couldn't have done it without you.

To my beloved husband, CA Vikrant Senapati thank you for your unconditional love, patience, and faith on me during this challenging journey. Your constant encouragement, understanding, and sacrifices made this achievement possible. You were my rock. I am eternally grateful for your presence in my life, and I dedicate this accomplishment to you.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW	1-51
1.1. INTRODUCTION	1-4
1.2. LITERATURE REVIEW	4-32
1.2.1. Polymer and Polymer Nanoparticles	4-15
1.2.1.1. Amino acids and their bio functions	4-5
1.2.1.2. Versatility of amino acids based copolymer nanoparticles based on their physicochemical properties	5-7
1.2.1.3. Functional poly(amino acid) copolymer nanoparticles and their synthesis strategies	7-9
1.2.1.4. Advantages of amino-acid based copolymers over amino-acid based homopolymers	9-11
1.2.1.5. Biomedical applications of polymers/poly(amino acid)s nanoparticles	11-13
1.2.1.6. Current clinical and preclinical status of nanomedicines	13-14
1.2.1.7. Rationale for developing a library of organ targeting copolymer Nanoparticles	14-15
1.2.2. Role of Computational Methods in Healthcare Therapeutics	15-16
1.2.3. Brief on Triple Negative Breast Cancer (TNBC)	16-22
1.2.3.1. Global statistics on TNBC	16-17
1.2.3.2. Challenges associated with the treatment of TNBC	17-18
1.2.3.3. Polymers and poly(amino acid)s based nanocarriers developed for TNBC	18-19
1.2.3.4. Potential role of phyto-drugs and their nanoparticle based delivery for TNBC systems used	19-20
1.2.3.5. Combination therapies in TNBC	21
1.2.3.6. Complications associated with off-target drug delivery and the importance of targeted therapies in TNBC	21-22
1.2.4. Wound Healing and Tissue Regeneration	22-27
1.2.4.1. Global statistics on wound healing and tissue regeneration	22-23
1.2.4.2. Origin and categories of wounds	23-24
1.2.4.3. Phases of wound healing	24-25
1.2.4.4. Polymers used for wound healing and tissue regeneration	25-26
1.2.4.5. Toxicity associated with crosslinkers and chemically crosslinked Copolymers	26-27
1.2.5. Angiogenesis	27-32
1.2.5.1. Polymers and amino acids-based nanoparticles: Their role in Angiogenesis	27-29
1.2.5.2. Mechanism of angiogenesis induction	29-30
1.2.5.3. Models and methods used for Accessing Angiogenesis	30-31
1.2.5.4. Role of Image processing tool in angiogenesis over conventional tools	31-32
1.3. MOTIVATIONS	32-35
1.3.1. Medical Needs and Clinical Challenges	32-33
1.3.2. Customization and Tailoring	33
1.3.3. Sustainability Consideration	33-34

1.3.4. Regulatory Support and Market Demand	34
1.3.5. Scientific Advancement	34-35
1.3.6. Ethical Consideration	35
1.4. OBJECTIVES WITH JUSTIFICATIONS	35-37
Objective 1	35-36
Objective 2	36
Objective 3	36
Objective 4	37
1.5. REFERENCES	37-51
CHAPTER 2: MATERIALS AND METHODOLOGIES	52-79
2.1. INTRODUCTION	52
2.2. MATERIALS	52-53
2.3. METHODOLOGIES	53-77
2.3.1. Synthesis and Modification of NPs	53-57
2.3.1.1. Synthesis of <i>N</i> -acryloyl glycine (NAG) monomer	53-54
2.3.1.2. Synthesis of <i>N</i> -acryloyl- <i>L</i> -phenylalanine (NAPA) methyl ester monomer	54-55
2.3.1.3. Synthesis of p(NAG- <i>co</i> -NAPA) _(x,y) copolymer library NPs	55
2.3.1.4. Folate conjugation of p(NAG- <i>co</i> -NAPA) _(1,4) copolymer NPs	55-56
2.3.1.5. Synthesis of p(NAG- <i>co</i> -NAPA) _{wc} copolymer NPs	56
2.3.1.6. Development of p(NAG- <i>co</i> -NAPA) _{wc} nanoformulations	56-57
2.3.2. Characterization Techniques of NPs	57
2.3.3. Colloidal Stability And Morphological Studies of NPs	58-59
2.3.3.1. CMC Determination	58-59
2.3.4. Biodegradation Study of NPs	59
2.3.5. Computational Studies of NPs	59-65
2.3.5.1. Network Pharmacology	59-60
2.3.5.2. Molecular Docking	60
2.3.5.3. Molecular Dynamics Simulation (MD)	61-62
2.3.5.4. Image processing tools	63-65
2.3.5.4.1. Processing of microscopic images through GLCM	63
2.3.5.4.2. Quantitative measurement of angiogenesis using GLCM	63-65
2.3.5.4.3. Hardware and Software used for angiogenesis analysis	65
2.3.6. Drugs Loading And Release (%) Determination	65-67
2.3.6.1. Loading of Drugs	65-66
2.3.6.2. <i>In vitro</i> release study (Encapsulation Efficiency % (EE%) and Loading Content % (LC%))	66
2.3.6.3. Mathematical Modeling	66-67
2.3.7. <i>In vitro</i> Studies of NPs	67-73
2.3.7.1. MTT assay (Cell viability and Cytotoxicity assay)	67
2.3.7.2. Evaluation of IC ₅₀ and combination index (CI)	67-68
2.3.7.3. Hemolysis Study	68
2.3.7.4. Cell migration and proliferation (Wound Scratch assay)	68
2.3.7.5. Cell Cycle Study Through FACS	69
2.3.7.6. Apoptosis/ Necrosis Assay Through FACS	69
2.3.7.7. Determination of Intracellular ROS Generation and Effect On	

Mitochondrial Membrane Potential (MMP) Through FACS	69-70
2.3.7.8. Cellular Internalization Mechanism Through FACS	70
2.3.7.9. Cellular Uptake Through Confocal Microscopy	70-71
2.3.7.10. Estimation of extracellular MMP-2 and MMP-9 expression through Gelatin Zymography	71
2.3.7.11. Reverse Transcriptase polymerase chain reaction (RT-PCR)	72-73
2.3.7.12. Tube formation assay	73
2.3.8. <i>In ovo</i> Study of NPs	73-74
2.3.8.1. Chorioallantoic Membrane (CAM/CEMA) Assay	73-74
2.3.9. <i>In vivo</i> Studies of NPs	74-77
2.3.9.1. Animal Handling and Ethics	74
2.3.9.2. Bio-distribution Studies	74-75
2.3.9.3. Dermal Irritation Study	75
2.3.9.4. Wound Healing Study	75-76
2.3.9.5. Histological Analysis	76
2.3.9.6. Immunochemical Parameters	76
2.3.9.7. Reverse Transcriptase polymerase chain reaction (RT-PCR)	76-77
2.4. STATISTICAL ANALYSIS	78
2.5. REFERENCES	78-79
CHAPTER 3: RESULTS AND DISCUSSION	80-217
CHAPTER 3 (PART I)	
3.1. Organ Targeting Drug Delivery Systems (OTDDS) of poly[(<i>N</i>-acryloyl glycine)-<i>co</i>-(<i>N</i>-acryloyl-<i>L</i>-phenylalanine methyl ester)] Copolymer Library and Effective treatment of Triple Negative Breast Cancer	80-114
3.1.1. Abstract	80
3.1.2. Introduction	81-85
3.1.3. Experimental	85-89
3.1.4. Results and Discussion	89-110
3.1.5. Summary and Conclusions	110-111
3.1.6. References	111-114
CHAPTER 3 (PART II)	
3.2. Co-delivery of Dihydroartemisinin and Piperine by Folate decorated poly[(<i>N</i>-acryloyl glycine)₁-<i>co</i>-(<i>N</i>-acryloyl-<i>L</i>-phenylalanine methyl ester)₄] copolymer for Triple Negative Breast Cancer Treatment	115-140
3.2.1. Abstract	115-116
3.2.2. Introduction	116-119
3.2.3. Experimental	119-122
3.2.4. Results and Discussion	123-137
3.2.5. Summary and Conclusions	137-138
3.2.6. References	138-140
CHAPTER 3 (PART III)	
3.3. Self-assembled Amino-based copolymer Nanoparticles for Wound Healing and tissue regeneration: structure studied through Molecular Dynamic Simulation	141-183
3.3.1. Abstract	141
3.3.2. Introduction	142-145
3.3.3. Experimental	145-148

3.3.4. Results and Discussion	149-180
3.3.5. Summary and Conclusions	180-181
3.3.6. References	181-183
CHAPTER 3 (PART IV)	
3.4. Angiogenic properties of Poly(<i>N</i>-acryloyl-glycine)-<i>co</i>-(<i>N</i>-acryloyl-<i>L</i>-phenylalanine methyl ester) nanoparticles: Quantitative Assessment via Gray Level Co-occurrence	
Matrix based Image Processing	184-217
3.4.1. Abstract	184-185
3.4.2. Introduction	185-189
3.4.3. Experimental	189-191
3.4.4. Results and Discussion	192-213
3.4.5. Summary and Conclusions	214
3.4.6. References	214-217
CHAPTER 4. SUMMARY, CONCLUSIONS AND FUTURE SCOPES	
4.1. Summary and Conclusions	218-223
4.2. Future scopes of Present work	223-224
Appendix 1	
Chapter 3. Results and Discussion (Part I)	225-246
Appendix 2	
Chapter 3. Results and Discussion (Part II)	247-254
Appendix 3	
Chapter 3. Results and Discussion (Part III)	255-265
Appendix 4	
Chapter 3. Results and Discussion (Part IV)	266-274

LIST OF FIGURES

Figure 1.1. Synthetic strategies of functional amino acid polymers.....	8
Figure 1.2. Represents biomedical applications of polymers/poly(amino acid) NPs.....	11
Figure 1.3. Represents four stages of the wound healing process.....	24
Figure 3.1.1. Physicochemical properties of library NPs (P1 to P5) with p(NAG) and p(NAPA) as references. Fig. (a) Stack plots of ¹ H NMR spectra, (b) stacked FTIR spectra of copolymers (dashed lines are representing the overlapped peaks in between reference NPs and copolymers), (c) UV-Vis spectra, (d) XRD, (e) TGA, (f) DSC and (g) MALDI-ToF (weight average molecular weight (\bar{M}_w), number average molecular weight (\bar{M}_n), and polydispersity indexes (PDI) are summarized for copolymer NPs (P1-P5), respectively.....	92
Figure 3.1.2. Morphology and colloidal stability studies of copolymer NPs. Fig. (a1-a3), (b1-b3), (c1-c3), (d1-d3) and (e1-e3) HR-TEM images of P1-P5 NPs at 0.5 μ m and 200 nm magnification with their SAED patterns, respectively, (f) DLS and Zeta potential, and (g) CD spectra of P1-P5 NPs with p(NAG) and p(NAPA) as references, measured with 250 μ g/mL concentration in MilliQ at 25°C.....	94
Figure 3.1.3. Cytocompatibility and hemocompatibility of OTDDNs. Fig. (a-d) Cytocompatibility against L929, (e-h) A549 and MDA-MB-231 cell lines and (i-l) hemocompatibility of P2, P3, P4 and P5 NPs, respectively at different concentrations. For all the figures 3.1.3(a-l) statistical significance values are provided in supplementary (Table S3.1.3.-S3.1.6).....	96
Figure 3.1.4. <i>In vivo</i> biodistribution of OTDDNs. (a) IVIS imaging of NPs at 1, 6, 12 and 24 h, (b-e) average radiance at concerned time period in different body organs such as Lungs, Heart, Liver, Kidney and Breast, respectively and (g) table with indications of organ specificity ('+': targeted, '+++': highly target specific and '-': non targeted).....	98
Figure 3.1.5. Network pharmacology and molecular docking results of piperine and DHA against TNBC. Fig. (a) and (b) show target protein network for piperine and DHA, respectively, (c) Venn diagram shows the common gene targets by piperine and DHA responsible for TNBC, (d) Interrelated network map of top 40 genes target of piperine and DHA and (e) gene expression responsible for TNBC pathways, (f) binding energy, and (g) K_i for target proteins of piperine and DHA. (g) Binding energy, and (i) K_i for the combination of piperine and DHA with paclitaxel. The colors in Figure 3.1.5.(e) shows the p-values for each term, with lower p-values having darker colours. The dot size demonstrates the number of genes associated with each pathway.....	100
Figure 3.1.6. Sequential Docking for 3D complex structure of β tubulin, CXCR2, Caspase 9, BCL-2, PR, ER α , EGFR, CDK2, with piperine and DHA in combination. In ligplots, green colour lines represent the H-bonds between ligands and amino acid residues and red circles represent the common polar and nonpolar hydrophobic interactions between the ligands....	102
Figure 3.1.7. Thermal stability, <i>in vitro</i> cytotoxicity and migratory effect of NFs in MDA-MB-231 cells. Fig. (a) TGA for P4, PP4 and DP4, (b) <i>in vitro</i> drug release % of NFs at different pH, (c-e) <i>in vitro</i> treatment efficiency of NFs studied against TNBC (MDA-MB-231) with different concentrations, (f) and (g) represent the change in width (%) and rate of migration (%), respectively calculated from the microscopic images (i) by Fiji imageJ software, (h) Dixon plot	

shows the 1/V vs concentration: for calculating enzymatic inhibition constant (K_i), and (g) microscopic images of wound scratch assay (scale: 100µm).....105

Figure 3.1.8. Flow cytometry study of the NPs and Co-NPs_(7:3). Fig. (a) Annexin V/ PI flow cytometry study, (b) cell cycle analysis, (c) ROS quantification and (d) mitochondrial membrane potential study of P4, PP4, DP4 and Co-NPs_(7:3) at 350µg/mL with unstained (only cells) and control (only dye).....109

Figure 3.2.1. Physicochemical characterization of P4 and fP4 NPs. Fig. (a) FTIR of P4, FA and fP4 NPs, (b) UV-Vis of P4 and fP4 NPs, (c1) and (c2) HR-TEM images of P4 and fP4 and (c3) and (c4) SAED pattern of (c1) and (c2), respectively. Yellow dash line circle in figure c2 represents the conjugation of FA over P4 NPs.....124

Figure 3.2.2. Thermal stability, *in vitro* drug release and release kinetics study of fP4 NPs, fPP4 and fDP4 NFs. Fig. (a) and (b) TGA and XRD of fP4 NPs, fPP4 and fDP4 NFs, (c) and (d) *in vitro* drug release % of NFs at pH 6.8 and 7.4, (e)-(h) mathematical model fitting of drug release kinetics data in six different standard models (Zero, First, Higuchi, Hixson Crowell, Weibull, and Korsmeyer-Peppas), and (i) regression coefficient (R²) of two best fitted mathematical models.....127

Figure 3.2.3. *In vitro* cytotoxicity and migratory effect of NFs in MDA-MB-231 cells. Fig. (a)-(d) treatment efficiency of NPs and NFs studied against TNBC with different concentrations, (e) and (f) the change in width (%) and rate of migration (%), respectively calculated from the microscopic images (g) by Fiji imageJ software, and (g) microscopic images of wound scratch assay (scale: 50µm). For figure (b-d) all the concentrations are showing significant difference of ‘***’ with control.....129

Figure 3.2.4. Cellular uptake study of P4, fP4 NPs, fPP4, fDP4 and Co-NFs_(8:2). Fig. (a) the cellular internalization mechanism of Rh-P4 NPs through flow cytometry, and (b) morphological changes study due to NFs through confocal microscopy in MDA-MB-231 cells (scale: 50µm). DAPI (blue), Phalloidin (green), MitoSox (red) used for nuclear, actin filament and mitochondrial ROS staining.....131

Figure 3.2.5. Annexin-V/PI flow cytometry study, (b) cell cycle analysis, quantification of (c) ROS and (d) MMP of P4, fP4, fPP4, fDP4 and Co-NFs_(8:2) at 280µg/mL with unstained (only cells) and control (only dye) samples.134

Figure 3.2.6. Modulation in expressions of potential TNBC biomarkers due to treatment with developed NFs. Fig. (a) represents the expression of MMP-2 and MMP-9 through gelatin zymography assay (CM: Conditioned media), and (b) expression of MKi67IP, STAT3, DNMT3B, EGFR, Bcl2, CDK2 and Casp9 through RT-PCR study of post treatment with NFs. For figure (b) all the NFs are showing significant difference of ‘***’ with P4 NPs for all the biomarkers.....136

Figure 3.3.1. Physicochemical properties of p(NAG-co-NAPA)_{wc} NPs. Fig. (a) ¹H NMR spectra, (b) FTIR spectra, (c) TGA and DTGA thermograms, (d) DSC thermogram and (e) XRD pattern of p(NAG-co-NAPA)_{wc} NPs. Inset image of (e) is the SAED pattern for p(NAG-co-NAPA)_{wc} NPs.....153

Figure 3.3.2. Size, shape, morphology and colloidal stability of p(NAG-co-NAPA)_{wc} NPs. Fig. (a) FESEM, (b) HRTEM image (scale bar: 200 nm), (c) DLS, (d) AFM, (e) particle size distribution obtained from Fig. 2 (a), (f) Zeta potential, (g) and (h) CD spectra of p(NAG-co-

NAPA)_{wc} NPs at different concentrations and three different temperatures, respectively and (i) CMC of p(NAG-co-NAPA)_{wc} NPs.....156

Figure 3.3.3. Show the structural evolution of NAPA-NAG at three different temperatures (298K, 310K, and 315K) at 0, 40, 80 and 100ns. The dimers are represented as QuickSurf using VMD and other components of the solutions were omitted for visual clarity.....158

Figure 3.3.4. The radial distribution function between oxygen atoms in water molecules and (a) the carboxylic groups, (b) phenyl groups, (c) nitrogen atoms in dimers at different temperatures. The black, red and blue lines of figures represented the temperatures, 298, 310 and 315K, respectively. (d) radial distribution functions between phenyl carbon atoms at 1 and 4 positions at different temperatures, respectively, (e) Number of intramolecular hydrogen bonds between -COO and -NH atoms with the total number of hydrogen bonds between copolymer units at different temperatures, (f) distribution of end-to-end distance of the copolymers at different temperatures, (g) Change in SASA of polymers matrix in aqueous solution at different temperatures with the evolution time, (h) density distribution of copolymer and POPC membrane along the direction perpendicular to the membrane surface, and (i-j) side and top views of agglomerates of copolymers in water on POPC membrane at 310K, respectively.....161

Figure 3.3.5. Biocompatibility, hemocompatibility and proliferation nature of p(NAG-co-NAPA)_{wc} NPs. Shows (a) cell viability (%), (b) hemolysis (%) of p(NAG-co-NAPA)_{wc} NPs at different concentrations against L929 cells and rat erythrocytes, respectively. The inset image of figure 3.3.5(b) represents the micro-centrifuge tubes showing hemolysis at 2 and 8h. MTT of p(NAG-co-NAPA)_{wc} NPs shows no significant difference for both L929 and hemolysis (%) of NPs are non-significant with respect to the control (-ve) and significant (*) with respect to the control (+ve) for 2 and 8h, respectively. Hemolysis (%) for 500µg/mL is significant (**) with respect to the control (-ve) at 8h. Fig. (c) Represents the microscopic images of the wound scratch assay of p(NAG-co-NAPA)_{wc} at 0, 24 and 48h taken at 10X magnification with a scale bar of 100µm, (d) and (e) Wound closure (%) and Rate of wound closure (%) of L929. rBCPs represents p(NAG-co-NAPA)_{wc} NPs. Data are given as mean ±SD (n=3) (*p ≤ 0.05, **p ≤ 0.05-0.01, ***p ≤ 0.05-0.001 and ns: non-significant).....165

Figure 3.3.6 Angiogenic effect of p(NAG-co-NAPA)_{wc} NPs. Fig. (a) *In ovo* CEMA assay in the presence of p(NAG-co-NAPA)_{wc} NPs support the branching angiogenesis in dose dependent manner. (b)-(e) represents several % changes in angiogenic parameters in percentage like Explant area, Vessel Area, Junction Density and Mean-E-Lacunararity, respectively in time and dose dependent manner.....168

Figure 3.3.7. *In vivo* skin irritation study. (a1-a4) Camera photographs of skin irritation study captured at 0h (before treatment) and (b1-b4) at 48h (after treatment), (c1-c4) histology images of H&E staining of tissue samples collected from b1-b4 rat skin at 20X magnification, and (d) calculation of irritation score based on occurrence of erythema and edema after 48h of treatment. The scale or erythema and edema are given in Table S3.3.4. rBCP NF represents p(NAG-co-NAPA)_{wc} NPs based nanoformulation. Data are given as mean ± SD (n=3) (*p ≤ 0.05, **p ≤ 0.05-0.01, ***p ≤ 0.05-0.001 and ns: non-significant).....170

Figure 3.3.8. Represents *in vivo* wound healing results. Fig. (a) Timeline of *in vivo* animal experiment followed in this work, (b) Optical microscopy images of wounds in three different groups (Control (b1-b5), Base (b6-b10) and rBCP NF (b11-b15) acquired in high resolution camera on 0th, 4th, 7th, 10th and 13th days and (b16-b18) histology images of H&E staining of healed tissue on 15th day of post treatment of control, base and rBCP NF, respectively, acquired

at 20X magnification, (c) Relative wound area (%) at five different days (0th, 4th, 7th, 10th and 13th) remaining to heal, and (d) Significant difference of mean wound area on 13th day using the Tukey test to compare the mean in between three different groups. In figure 3.3.7(d), C: Control group, B: Base group and NF: rBCP nanoformulation. Other than represented statistical significance, all other combinations are significant with $P \leq 0.001$. rBCP NF represents p(NAG-co-NAPA)_{wc} NPs based nanoformulation. Data are given as mean \pm SD (n=3) (*P \leq 0.05, **P \leq 0.05-0.01, ***P \leq 0.05-0.001 and ns: non-significant).....172

Figure 3.3.9. Wound healing markers and real time expressions of selected genes during *in vivo* wound healing. Fig. (a) TNF- α , (b) IL-1 β , (c) IL-6, (d) CRP and (e) IGF-1 levels analyzed by ELISA on 0th day (before wound creation), 7th and 14th day. Each data point represents the average \pm SD of three independent determinations (p < 0.05). (f) and (g) Represents relative fold change in gene expressions (TNF- α , IL-1 β , PECAM-1, VEGFA and KDR) obtained from RT-PCR results. Other than represented statistical significance, all other combinations are significant with $P \leq 0.001$. rBCP NF represents p(NAG-co-NAPA)_{wc} NPs based nanoformulation. Data are given as mean \pm SD (n=3) (*P \leq 0.05, **P \leq 0.05-0.01, ***P \leq 0.05-0.001 and ns: non-significant).....175

Figure 3.4.1. ¹H NMR (500 Hz, CDCl₃ and DMSO-d₆) spectra for p(NAG-co-NAPA) NPs performed in (DMSO-d₆ and CDCl₃). The inset represents the possible arrangement of NAG, NAPA and DVB in p(NAG-co-NAPA) NPs. The corresponding bands with respect to chemical structure have been mentioned with bold letters in black colour.....194

Figure 3.4.2. Characterizations of p(NAG-co-NAPA) NPs. Fig. (a) FTIR spectra for p(NAG), p(NAPA), and p(NAG-co-NAPA) NPs, (b) UV-Vis spectra for p(NAG-co-NAPA), (c) Powder XRD for p(NAG-co-NAPA), p(NAG), and p(NAPA) and SAED pattern of p(NAG-co-NAPA) (inset image), (d) TGA of p(NAG-co-NAPA), p(NAG), and p(NAPA), (e) TGA and DTG for p(NAG-co-NAPA), and (f) DSC of p(NAG-co-NAPA). The dotted and dash lines drawn in the FTIR spectra represent common bands present in p(NAPA), p(NAG) and p(NAG-co-NAPA) and p(NAPA) and p(NAG-co-NAPA) NPs.....196

Figure 3.4.3. Morphology and colloidal stability of p(NAG-co-NAPA) NPs. Fig. (a) and (b) FESEM and HR-TEM image of p(NAG-co-NAPA) NPs at 500nm scale, respectively; (c) zeta potential of p(NAG-co-NAPA), (d) and (e) particle size distribution of Figure 3.4.3 (a) and (b), respectively; (f) Hydrodynamic diameter of p(NAG-co-NAPA), (g) and (h) CD spectra of p(NAG-co-NAPA), p(NAG) and p(NAPA) NPs, and serial 2-fold dilutions of p(NAG-co-NAPA) NPs, and (i) CMC of p(NAG-co-NAPA) NPs, where ‘C’ represents the concentration of NPs.....199

Figure 3.4.4. Biocompatibility and hemocompatibility of p(NAG-co-NAPA) NPs. Fig. (a), (b), (c) and (d) Cell viability (%) of p(NAPA) and p(NAG) NPs against L929, Raw 264.7, PC12 and HUVEC cells, respectively; (e) and (f) Cell viability (%) of p(NAG-co-NAPA) NPs in L929, Raw 264.7 and PC12 cell lines and HUVEC cells, respectively and (g) hemolysis (%) of p(NAG-co-NAPA) NPs. In cell viability case, for p(NAPA) and p(NAG) NPs, calculated p values are provided in supplementary file (see Table S1 and Table S2). For p(NAG-co-NAPA) NPs in all concentrations, against three different cells lines non-significant difference are observed with respect to control whereas for HUVEC cells with respect to control 5 and 200 μ g/mL are significant with ‘*’. For hemolysis, at 2h, all concentrations are showing significant difference with control (+ve) with ‘***’ and not significant (ns) with control (-ve). For 8h, all concentrations are showing significant difference with control (+ve) with ‘***’ and only 500 μ g/mL is showing significant difference with ‘***’202

Figure 3.4.5. Represents the microscopic images and binary images obtained after segmentation of blood vessels for p(NAG), p(NAPA) and p(NAG-co-NAPA) NPs with three different doses (1, 10 and 100µg) with control sample at five different time intervals (0, 2, 4, 8 and 24h). Fig. (a), (b) and (c) represents the raw images and (d), (e) and (f) represent the binary images after segmentation corresponding to (a), (b) and (c). The black arrows inside the microscopic images (a, b and c) represent the visual changes in images over dose and time. The black dashed circle drawn in p(NAPA) in 100µg dose represents the position where sample was added during the experiment.....204

Figure 3.4.6. Represents the three textural features extracted from GLCM based matrix. Fig. (a), (b) and (c) demonstrate the number of pixels in blood vessels; (d), (e) and (f) demonstrate the entropy; and (g), (h) and (i) demonstrate the energy for p(NAG), p(NAPA) and p(NAG-co-NAPA) NPs with three different doses (1, 10 and 100µg) with control sample at five different time intervals (0, 2, 4, 8 and 24h), respectively. The error % values are lying in between 10% and a corresponding Tables are provided in the supplementary file (see Table S3, Table S4 and Table S5).....205

Figure 3.4.7. Represents the two textural features extracted from GLCM. Fig. (a), (b) and (c) demonstrate Mean and (d), (e) and (f) demonstrate Contrast for p(NAG), p(NAPA) and p(NAG-co-NAPA) NPs with three different doses (1, 10 and 100µg) with control sample at five different time intervals (0, 2, 4, 8 and 24h), respectively. The error % are calculated and varying upto 10% (see Table S6 and Table S7).....207

Figure 3.4.8. Represents the two textural features extracted from GLCM based matrix. Fig. (a), (b) and (c) demonstrate dissimilarity and (d), (e) and (f) demonstrate variance for p(NAG), p(NAPA) and p(NAG-co-NAPA) NPs with three different doses (1, 10 and 100µg) with control sample at five different time intervals (0, 2, 4, 8 and 24h), respectively. The error% values are obtained upto 10% (see Table S8 and Table S9).....208

Figure 3.4.9. Dose dependent tube formation properties of p(NAG-co-NAPA) NPs. Fig. (a-d) and (e-h) represent bright field and calcein-am stained microscopic images of HUVEC cells treated with three different concentration of p(NAG-co-NAPA) NPs at 6h (scale bar: 400 µm); (i) explant area (%), (j) total vessel length (%), (k) total number of junctions (%), (l) mean-e-lacunarity (%) calculated by Angiotool and (m) number of pixels in blood vessels, (n) entropy, (o) energy and (p) mean calculated by GLCM texture features based Image processing tool respectively for obtained microscopic images (e-h) from tube formation assay. The corresponding error% values are provided in supplementary (Table S10 and Table S11)...210

Figure 3.4.10. Represents the significant change in textural features obtained from segmented images during the *in ovo* based angiogenesis study. Fig. (a) number of pixels in blood vessels, (b) entropy, (c) energy, and (d) mean for p(NAG), p(NAPA) and p(NAG-co-NAPA) NPs with the treatment of 10µg dose at 24h.....213

Figure S3.1.1. Schematic for the synthesis of p(NAG-co-NAPA)_(x:y) NPs.....225

Figure S3.1.2. (a) ¹H NMR and (b) ¹³C NMR of NAG.....226

Figure S3.1.3. (a) ¹H NMR and (b) ¹³C NMR of NAPA.....227

Figure S3.1.4: FTIR spectra of (a) NAG and (b) NAPA.....228

Figure S3.1.5. Represents stacked ¹³C NMR of p(NAG), p(NAPA), P1, P2, P3, P4,

and P5.....	228
Figure S3.1.6. MALDI-ToF spectra of p(NAG) NPs.....	229
Figure S3.1.7. MALDI-ToF spectra of p(NAPA) NPs.....	229
Figure S3.1.8. MALDI-ToF spectra of P1 NPs.....	230
Figure S3.1.9. MALDI-ToF spectra of P2 NPs.....	230
Figure S3.1.10. MALDI-ToF spectra of P3 NPs.....	231
Figure S3.1.11. MALDI-ToF spectra of P4 NPs.....	231
Figure S3.1.12. MALDI-ToF spectra of P5 NPs.....	232
Figure S3.1.13. HRTEM images of (a1-a3) p(NAG) and (b1-b3) p(NAPA) NPs.....	232
Figure S3.1.14. Cytotoxicity study of (a-c) p(NAG) and p(NAPA) NPs against L929, A549 and MDA-MB-231 cells and (d-e) P1 NPs against L929, A549 and MDA-MB-231 cells....	233
Figure S3.1.15. Hemolysis (%) of (a) p(NAG), (b) p(NAPA), (c) P1 NPs and (d) image representation of tubes at 2 and 8h for P2 to P5 NPs.....	233
Figure S3.1.16. HRTEM micrograph of P4 NPs incubated in SBF (pH 7.4). Results shows that after 7 days of incubation the P4 NPs degraded from 180-200 nm to fragments of 10-20 nm in size.....	234
Figure S3.1.17. TGA of P4, PP4 and DP4 NPs.....	234
Figure S3.1.18. Cell inhibition (%) shown by DP4:PP4 at different ratio. The final concentration is fixed to 400µg/mL.....	235
Figure S3.2.1: Cell inhibition (%) shown by DP4:PP4 at different ratio. The final concentration is fixed to 400µg/mL.....	253
Figure S3.3.1. ¹³ C NMR of p(NAG-co-NAPA) _{wc} NPs.....	254
Figure S3.3.2. UV-Vis spectra of p(NAG-co-NAPA) _{wc} NPs.....	255
Figure S3.3.3. MALDI-ToF spectra of p(NAG-co-NAPA) _{wc} NPs.....	255
Figure S3.3.4. (a) Size distribution by volume and (b) Combined plot for Particle size distribution by intensity and Particle size distribution by Volume.....	256
Figure S3.3.5. CD report showing the presence of 100% turns in p(NAG-co-NAPA) _{wc} nanoparticles in colloidal state.....	257
Figure S3.3.6. Topology of dimer unit (1NAPA-1NAG).....	258
Figure S3.3.7. Represents the aggregation behavior of hydrophobic phenyl groups present in NAPA units after 0ns, 40ns and 80ns simulation run in three different temperatures (298K, 310K and 315K).....	259

Figure S3.3.8. Represents the aggregation behavior of hydrophilic carboxyl groups present in NAG units after 0ns, 40ns and 80ns simulation run in three different temperatures (298K, 310K and 315K).....	260
Figure S3.3.9. Represents angle distribution between Ph ₁₄ -Ph ₁₄ at (a) 298K, (b) 310K, and (c) 315K.....	261
Figure S3.3.10. Represents (a) Number of Hydrogen bonds, and (b) Number of contacts in between copolymer and water.....	261
Figure S3.3.11. Thermodynamic equilibrium properties of the NAG-NAPA dimer system in aqueous media. (a) Potential energy of the system during the production run, (b) Number of intramolecular hydrogen bonds between –COO and –NH atoms, (c) SASA for dimer, at 298, 310 and 315 K in black, red and blue lines respectively, (d) RDF between carboxylic groups of dimer and oxygen atom of water molecules and (e) RDF between dimer units at every 10 ns time intervals.....	262
Figure S3.3.12. Represents the 10x microscopic images of CAM assay acquired to show the irritation effect of formalin in <i>in ovo</i> model after 24h of treatment.....	262
Figure S3.4.1. ¹³ C Solid-state NMR of p(NAG- <i>co</i> -NAPA) NPs.....	265
Figure S3.4.2. ¹ H NMR of p(NAG- <i>co</i> -NAPA) _{wc} NPs.....	266
Figure S3.4.3. Represents the MALDI-ToF spectrum of p(NAG- <i>co</i> -NAPA) NPs.....	266
Figure S3.4.4. Represents the agglomeration behavior of p(NAG- <i>co</i> -NAPA) NPs. (a) 2D and (b) 3D AFM images of p(NAG- <i>co</i> -NAPA) NPs at 10μm scale, (c) and (d) HR-TEM images of p(NAG- <i>co</i> -NAPA) NPs at 500nm at 200nm scale.....	267
Figure S3.4.5. Hemolysis (%) of p(NAG- <i>co</i> -NAPA) NPs. At 2h, all concentrations are showing significant difference with control (+ve) with ‘***’ and not significant (ns) with control (-ve). For 8h, all concentrations are showing significant difference with control (+ve) with ‘***’ and only 500μg/mL is showing significant difference with ‘***’	267

LIST OF SCHEMES

Scheme 3.3.1. Schematic represents the mechanism involved in the synthesis of NAG, NAPA, and p(NAG- <i>co</i> -NAPA) _{wc} NPs.....	150
Scheme 3.3.2. Schematic representation of p(NAG- <i>co</i> -NAPA) _{wc} NPs forming self-assembled nanostructure via physical cross-linking induced by π - π stacking.....	155

LIST OF TABLES

Table 1.1. List of Poly (amino acid)s used for various biomedical applications.....	12-13
Table 1.2. List of polymers and amino acid based nanocarriers used for TNBC treatment.....	19
Table 1.3. List of polymers used for wound healing and tissue regeneration.....	26
Table 1.4. List of polymer and scaffolds used for therapeutic applications.....	28
Table 1.5. List of different angiogenesis software with its advantages and disadvantages.....	32
Table 2.1. List of primer sequences of selected genes for RT-PCR study of MDA-MB-231 cells treated with NPs.....	72
Table 2.2. List of primer sequences of selected genes for RT-PCR study of NPs treated tissue sample.....	77
Table 3.1.1. Homopolymers and library of OTDDS [p(NAG-co-NAPA) _(x:y)] with different monomer ratios.....	86
Table 3.1.2. Physicochemical properties of P4, PP4 and DP4.....	104
Table 3.1.1. Physicochemical properties of fP4 NPs, fPP4 and fDP4 NFs.....	126
Table S3.1.1. List of chains, inhibitors and ions removed from protein structure before docking.....	235-236
Table S3.1.2. List of % of secondary structures present in different NPs of mini library.....	237
Table S3.1.3. Statistical significance of Cytotoxicity study of NPs against L929 cells.....	237
Table S3.1.4. Statistical significance of Cytotoxicity study of NPs against A549 cells.....	238
Table S3.1.5. Statistical significance of Cytotoxicity study of NPs against MDA-MB-231 cells.....	238
Table S3.1.6. Statistical significance of Hemolysis study of NPs at 2h and 8h.....	239
Table S3.1.7. List of proteins with their respective PDB ID considered for individual docking with ligands (piperine and DHA) and their binding energy, inhibition constant and amino acid residues.....	240-243
Table S3.1.8. Docking results of 8 selected proteins with combination of ligands (piperine followed by DHA).....	243-245
Table S3.1.9. Docking results of 8 selected proteins with combination of ligands (DHA followed by piperine).....	245-246
Table S3.2.1. R ² values for different mathematical models used to study the drug release kinetics.....	253
Table S3.2.2. List of constant values obtained for different mathematical models during fitting of drug release data.....	253
Table S3.3.1. Description of system used for MD Simulation.....	263
Table S3.3.2. Ingredients (%) used for oleaginous base preparation.....	263
Table S3.3.3. Qualitative assessment of oleaginous base and rBCP NFs.....	263
Table S3.3.4. Skin irritation assessment (Draize score determination).....	264
Table S3.4.1. Error% calculated for the Cell Viability study.....	268

Table S3.4.2. Error% calculated for the Cell Viability study of HUVEC cells.....	268
TableS3.4.3. Error% calculated for the number of pixels in blood vessels.....	268-269
Table S3.4.4. Error% calculated for entropy.....	269
Table S3.4.5. Error% calculated for energy.....	269-270
Table S3.4.6. Error% calculated for mean.....	270
Table S3.4.7. Error% calculated for contrast.....	270
Table S3.4.8. Error% calculated for dissimilarity.....	271
Table S3.4.9. Error% calculated for variance.....	271
Table S3.4.10. Error% calculated for from tube formation assay computed using Angiotool.....	271
Table S3.4.11. Error% calculated for from tube formation assay computed using Image processing tool.....	271

LIST OF ABBREVIATIONS

ATRP	Atom Transfer Radical Polymerization
AIBN	Azobisisobutyronitrile
AFM	Atomic Force Microscopy
BMP-2	Bone Morphogenetic Protein-2
BRCA	Breast Cancer Gene
BDDE	1,4-butanediol diglycidyl ether
BRAT	Batch Resourcing Angiogenesis Tool
BSA	Bovine Serum Albumin
CMC	Critical Micelle Concentration
CQDs	Carbon Quantum Dots
CAGR	Compound Annual Growth Rate
CAM	Chorioallantoic Membrane Assay
CPU	Central Processing Unit
CD	Circular Dichroism
CI	Combination Index
CRP	C-reactive Protein
CDK2	Cyclin-Dependent Kinase 2
CASP9	caspase 9
DFUs	Diabetic Foot Ulcers
DCE	Dynamic Contrast Enhanced
DHA	Dihydroartemisinin
DVB	Divinyl Benzene
DiD	1,1'-Dioctadecyl-3,3',3'-Tetramethylindodicarbocyanine
DMEM	Dulbecco's Modified Eagle Medium
DMSO-d ₆	Dimethyl Sulfoxide D ₆
DMSO	Dimethyl Sulfoxide
DCFHDA	2',7'-Dichlorodihydrofluorescein Diacetate
DEPC	Diethylpyrocarbonate
DSC	Differential Scanning Calorimetry
DNS	Dextrose Normal Saline
DAPI	4',6-diamidino-2-phenylindole
DABCO	1,4-Diazabicyclo[2.2.2]octane
DNMT3B	DNA Methyltransferase 3 beta
ER	Estrogen Receptor
ECM	Extracellular Matrix
EDC.HCl	1-Ethyl-3-(3-Dimethylaminopropyl)Carbodiimide Hydrochloride
EE %	Encapsulation Efficiency %
EGFR	Epidermal Growth Factor Receptor gene
ELISA	Enzyme-Linked Immunoassay
EC	Endothelial Cells
FDA	Food and Drug Administration;
FTIR	Fourier Transform Infrared Spectroscopy
FESEM	Field Emission Scanning Electron Microscope
FAO	Fatty Acid Oxidation
FGF	Fibroblast Growth Factor

FR α	Folate Receptor α
GSH	Glutathione
GLCM	Gray Level Co-Currence Matrix
GAPDH	Glyceraldehyde-3-phosphate Dehydrogenase
HA	Hydroxyapatite
HER2	Human Epidermal Growth Factor Receptor 2
HD	Hexadecane
HIF-1 α	Hypoxia-Inducible Factor 1-Alpha
HUVECs	Human Umbilical Vein Endothelial Cells
HR-TEM	High-Resolution Transmission Electron Microscopy
ICG	Indocyanine Green
iNOS	Inducible Nitric Oxide Synthase
IL	Interleukins
IL-1 β	Interleukin-1 beta
IL-6	Interleukin-6
IGF	Insulin-like Growth Factor
KOH	Potassium Hydroxide
KDR	Kinase Insert Domain Receptor gene
LC%	Loading Capacity %
MMT	Montmorillonite
MD	Molecular Dynamics
MMPs	Mitochondrial Membrane Potential
micro CT	Microcomputed Tomography
MTT	3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide
MALDI-ToF	Matrix-Assisted Laser Desorption/Ionization Time-of-Flight
MMP-2	Matrix Metalloproteinases-2
MMP-9	Matrix Metalloproteinases-9
MKi67	Marker of Proliferation Ki-67
NPs	Nanoparticles
NCA	N-Carboxy Anhydrides
NMP	Nitroxide-Mediated Polymerization
NFA	Network Formation Assay
NHS	N-hydroxysuccinimide
NAG	<i>N</i> -acryloyl glycine
NAPA	<i>N</i> -acryloyl- <i>L</i> -phenylalanine methyl ester
NFs	Nanoformulations
NMR	Nuclear Magnetic Resonance
OTDDS	Organ Targeting Drug Delivery Systems
PCL	Polycaprolactone
PLA	Poly(lactic acid)
PGA	Poly(glycolic acid)
PLGA	Poly(lactic-co-glycolic acid)
PEG	Poly(ethylene glycol)
PEO	Poly(ethylene oxide)
PMAG-b-PAA	Poly(2-deoxy-2-methacrylamido-D-glucose)-b-poly(amino acid)
PEI	Polyethyleneimine
PU	Polyurethane

PHB	Polyhydroxyburate
PR	Progesterone Receptor
PARP	Poly(ADP-ribose) polymerase
PTT	Photo Thermal Therapy
PEGDE	poly (ethylene glycol) diglycidyl ether
PLGF	Placental Growth Factor
PDGF	Platelet-Derived Growth Factor
p(NAG)	Poly(<i>N</i> -acryloyl glycine)
p(NAPA)	Poly(<i>N</i> -acryloyl- <i>L</i> -phenylalanine methyl ester)
p(NAG- <i>co</i> -NAPA)	Poly(<i>N</i> -acryloyl glycine- <i>co</i> - <i>N</i> -acryloyl- <i>L</i> -phenylalanine methyl ester)
p(NAG- <i>co</i> -NAPA) _{wc}	Poly(<i>N</i> -acryloyl glycine- <i>co</i> - <i>N</i> -acryloyl- <i>L</i> -phenylalanine methyl ester) _{without} crosslinker
PDB	Protein Data Bank
PBS	Phosphate Buffer Saline
PDII	Primary Dermal Irritation Index
PECAM-1	Platelet Endothelial Cell Adhesion Molecule 1
Q-VAT	Quantitative Vascular Analysis Tool
ROP	Ring-Opening Polymerization
RAFT	Reversible Addition-Fragmentation Chain Transfer
ROMP	Ring-Opening Metathesis Polymerization
ROS	Reactive Oxygen Species
RAVE	Rapid Analysis Of Vessel Elements
REAVER	Rapid Editable Analysis Of Vessel Elements Routine
RAM	Random-Access Memory
RBCs	Red Blood Cells
RT-PCR	Reverse transcription polymerase chain reaction
SF	Silk Fibroin
SDS	Sodium Dodecyl Sulphate
SBF	Simulated Body Fluid
STAT3	Signal Transducer and Activator of Transcription 3
TNBC	Triple Negative Breast Cancer
TME	Tumor Microenvironment
TMB	Tumor Mutation Burden
TGF	Transforming Growth Factor
TNF- α	Tumor Necrosis Factor- α
TGA	Thermogravimetric analysis
USWR	U.S. Wound Registry
UV-Vis	Ultraviolet-Visible
VEGF	Vascular Endothelial Growth Factor
VLUs	Venous Leg Ulcers
WHO	World Health Organization